Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479354 | 0.86 | MAPT (0.39) | MAPTMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL7431251 | 0.85 | MAPT (0.45) | MAPTMEN1KMT2AHTT | |
| SCHEMBL7680090 | 0.82 | MEN1 (0.39) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7682360 | 0.81 | L3MBTL1 (0.42) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6487215 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAGAA | |
| SCHEMBL10637253 | 0.76 | ALDH1A1 (0.43) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6974516 | 0.75 | ALDH1A1 (0.41) | L3MBTL1HTTALDH1A1CYP2C19TNF | |
| SCHEMBL6487800 | 0.75 | CNR1 (0.38) | MAPTMEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL6478745 | 0.74 | ALDH1A1 (0.41) | MAPTMEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL121043 | 0.74 | PSEN1 (0.40) | MAPTHTTALDH1A1CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861530-B2 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-6492392-B1 | INHIBITING TUMOR CELL PROLIFERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| US-20020137770-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137770-A1 | Piperidine derivatives | CIP2A, PARP2, TP53 | L3MBTL1 3244/4885MAPT 2999/4885MEN1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.